KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBIT Margin: 2011-2024

Historic EBIT Margin for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to 16.37%.

  • Esperion Therapeutics' EBIT Margin rose 1963.00% to -11.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.67%, marking a year-over-year decrease of 1524.00%. This contributed to the annual value of 16.37% for FY2024, which is 15009.00% up from last year.
  • Esperion Therapeutics' EBIT Margin amounted to 16.37% in FY2024, which was up 112.24% from -133.72% recorded in FY2023.
  • Esperion Therapeutics' 5-year EBIT Margin high stood at 16.37% for FY2024, and its period low was -289.02% during FY2021.
  • For the 3-year period, Esperion Therapeutics' EBIT Margin averaged around -118.39%, with its median value being -133.72% (2023).
  • As far as peak fluctuations go, Esperion Therapeutics' EBIT Margin tumbled by 23,567bps in 2021, and later spiked by 15,009bps in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' EBIT Margin stood at -53.35% in 2020, then tumbled by 23,567bps to -289.02% in 2021, then spiked by 5,119bps to -237.83% in 2022, then surged by 10,411bps to -133.72% in 2023, then skyrocketed by 15,009bps to 16.37% in 2024.